Cubed Biotech Inc. (“Cubed” or the “Company”), a psychedelic biotechnology company focusing on psychedelic research and development, proudly announces the approval of its application for a Dealer's License (the “Dealer’s License”) by Health Canada. The Dealer’s License will allow Cubed to operate within the legal framework and contribute to the burgeoning field of psychedelic research and therapies. This momentous achievement marks a significant milestone for Cubed, as it enables the research and development (“R&D”) and production of psilocybin, psilocin, mescaline, dimethyltryptamine (“DMT”), and harmala alkaloids with an ISO8 certification.
With the Dealer's License in place, Cubed intends to leverage its expertise and facilities to produce psilocybin, psilocin, mescaline, DMT, and harmala alkaloids from both natural and synthetic sources. The Company's ISO8 certification ensures adherence to strict guidelines and industry best practices with a view to quality, safety, and purity.
Cubed’s mission is to explore the therapeutic potential of psychedelics to address a wide range of mental health disorders, including treatment-resistant depression, anxiety, and post-traumatic stress disorder. The Company's R&D efforts aim to uncover new insights into the mechanisms of action of psychedelic compounds and develop innovative treatment modalities to improve patient outcomes.
"This milestone is a testament to the hard work and dedication of our team at Cubed. We are excited to receive our Dealer's License from Health Canada, which further validates our commitment to advancing psychedelic medicine," said Adam B. Coape-Arnold, Chief Executive Officer of Cubed. "We believe that psychedelic compounds have the potential to revolutionize mental health treatments, and this license will enable us to contribute to the R&D in this transformative field."
"Research Update: “Understanding Reward Pathways in the Brain”
Working with a grant of $575,000 from the Quebec Biopharmaceutical Consortium (CQDM), principal investigator Dr. Rosemary Bagot of McGill University (“McGill”) is making significant advances with our sponsored research of psilocybin. Her lab has developed a translationally relevant mouse model to probe how stress changes the way the brain processes reward. Research using this model could have significant implications for the treatment of depression, addiction and other psychiatric disorders. We congratulate Dr. Bagot and her team on their work and look forward to future breakthroughs from Dr. Bagot’s research. We are proud to support Dr. Bagot's research and are excited about the possibilities that this advance could unlock.
Cubed is now poised to accelerate its research initiatives and collaborations with renowned North American academic institutions, as well as contribute to the growing body of evidence supporting the therapeutic use of psychedelic compounds. The Company remains committed to responsible research practices, ethical standards, and fostering collaborations that drive innovation in the psychedelic space.